Furthermore, higher expression of ANKRD11 was associated with poor prognosis in luminal A subtype of ER+ breast cancer (Fig. 4o) but opposite outcome in ER− subset (Supplementary Fig. 2a), implying a role of ANKRD11 in mediating resistance to endocrine therapies in ER+ breast cancer. This evidence concerns the gene ANKRD11 and breast cancer.